Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
Boada, Merce 1,2; Lopez, Oscar L. 3; Olazaran, Javier 4,5; Nunez, Laura 6; Pfeffer, Michael 7; Puente, Orlando 8; Pinol-Ripoll, Gerard 9; Gamez, Jose E. 10; Anaya, Fernando 11; Kiprov, Dobri 12; Alegret, Montserrat 1; Grifols, Carlota 6; Barcelo, Miquel 6; Bozzo, Jordi 6; Szczepiorkowski, Zbigniew M. 13,14; Paez, Antonio 6; the AMBAR Trial Group
[Article]
Alzheimer's & Dementia.
18(7):1314-1324, July 2022.
(Format: HTML, PDF)